MEDIA STATEMENT
For Immediate Release
April 2, 2014
LHSC fully supports any reviews conducted to ensure system safeguards are in place that prevent a recurrence of this issue. Similar to the Theissen report, the Standing Committee's report released late yesterday highlights breakdowns in the system and also recommends further actions across several stakeholders to strengthen treatment safeguards.
From a hospital perspective, we have the fullest confidence in our pharmacy and cancer teams. Everyone's goal in this is to ensure safety and quality and to restore patient confidence in their health system. Last year, LHSC implemented process changes to safeguard against any similar incident occurring and we will continue to support any further reviews that may be conducted surrounding the chemotherapy dosage issue.
Murray Glendining
Acting President and CEO
London Health Sciences Centre
-30-
